

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BRIAN MRLUK Examiner #: 76173 Date: 2/16/05
Art Unit: 1751 Phone Number 30 272-1321 Serial Number: 101668,535
Mail Box and Bldg/Room Location: PEM 9445 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: AMPHIPHILIC SURFACTANTS BASED UPON ALKYL POLYGLUCOSIDE

Inventors (please provide full names): 1) DAVID ANDERSON 2) DEAN A SMITH
3) ANTHONY J. O'LENICK, JR.

Earliest Priority Filing Date: NONE (CASE WAS FILED 9/24/03)

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

PLEASE SEARCH THE STRUCTURES OF THE 2 COMPOUNDS
RECITED IN CLAIM 1. PLEASE NOTE THAT DEPENDENT
CLAIMS 2-9 FURTHER LIMIT THE VARIABLES RECITED
IN CLAIM 1.

- THANKS

(NOT MUCH REAL CLOSE OUT THERE.)

STAFF USE ONLY


	Type of Search	Vendors and cost where applicable
Searcher: <u>ELP</u>	NA Sequence (#) _____	STN <u>\$292.55</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>(3)</u>	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic <u>(1)</u>	Dr.Link _____
Date Completed: <u>2-25-05</u>	Litigation <u>(1)</u>	Lexis/Nexis _____
Searcher Prep & Review Time: <u>5</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>60</u>	Other _____	Other (specify) _____

Claims;

What is claimed;

1. A surfactant compositions which comprises a mixture of compounds conforming to the following structures:

(a)





(THESE MAY HAVE BEEN INDEXED AS THE ACYCLIC, OPEN-CHAIN SUGAR, SO WE HAD TO SEARCH BOTH WAYS, WHICH ACCOUNTS FOR WHY SOME OF THE ANSWERS LOOK LIKE ██████ THEY DO.)

wherein;

R is alkyl having 8 to 22 carbon atoms;


R¹, R², R³. and R⁴ are independently selected from the group consisting of



and H, with the proviso that R¹, R², R³. and R⁴ are not all H;

and



(b)



wherein;

R is alkyl having 8 to 22 carbon atoms;


$\text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}$ and R^{11} are independently selected from the group consisting of



and H, with the proviso that $\text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}$ and R^{11} are not all H.

2. A surfactant compositions of claim 1 wherein;


R^1 , R^2 , R^3 . and R^4 are independently selected from the group consisting of



and H, with the proviso that R^1 , R^2 , R^3 . and R^4 are not all H;

and


R^5 , R^6 , R^7 , R^8 ; R^9 , R^{10} and R^{11} are independently selected from the group consisting of



and H, with the proviso that R^5 , R^6 , R^7 . R^8 , R^9 R^{10} and R^{11} are not all H.

3. A surfactant compositions of claim 1 wherein


R^1 , R^2 , R^3 . and R^4 are independently selected from the group consisting of



and H, with the proviso that R^1 , R^2 , R^3 . and R^4 are not all H;

and

R^5 , R^6 , R^7 , R^8 ; R^9 , R^{10} and R^{11} are independently selected from the group consisting of



and H, with the proviso that R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and R^{11} are not all H.

4. A surfactant compositions of claim 2 wherein R is $C_{12}H_{25}$.
5. A surfactant compositions of claim 2 wherein R is $C_{10}H_{21}$.
6. A surfactant compositions of claim 2 wherein R is $C_{22}H_{42}$.
7. A surfactant compositions of claim 3 wherein R is $C_{12}H_{25}$.
8. A surfactant compositions of claim 3 wherein R is $C_{10}H_{21}$.
9. A surfactant compositions of claim 3 wherein R is $C_{22}H_{42}$.

=> file reg

FILE 'REGISTRY' ENTERED AT 16:11:51 ON 25 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

=> d his

L1 FILE 'LREGISTRY' ENTERED AT 15:29:30 ON 25 FEB 2005
STR

L2 FILE 'HCAPLUS' ENTERED AT 15:51:04 ON 25 FEB 2005
52934 S ANDERSON ?/AU
L3 145777 S SMITH ?/AU
L4 301 S OLENICK ?/AU OR O LENICK ?/AU OR LENICK ?/AU
L5 0 S L2 AND L3 AND L4
L6 0 S L4 AND L2
L7 8 S L4 AND L3
L8 5000 S ANDERSON D?/AU
L9 14670 S SMITH D?/AU
L10 3 S L8 AND L9
L11 11 S L7 OR L10
SEL L11 1-11 RN


L12 FILE 'REGISTRY' ENTERED AT 15:54:10 ON 25 FEB 2005
54 S E1-E56
L13 13 S L12 AND N/ELS
L14 41 S L12 AND O/ELS
L15 11 S L13 AND L14
L16 4 S L1
L17 STR L1
L18 0 S L17
L19 153 S L1 FUL
SAV L19 MRU535/A
L20 0 S L17 SSS SAM SUB=L19
L21 12 S L17 SSS FUL SUB=L19
SAV L21 MRU535A/A

L22 FILE 'CAOLD' ENTERED AT 16:09:06 ON 25 FEB 2005
0 S L21

L23 FILE 'ZCAPLUS' ENTERED AT 16:09:12 ON 25 FEB 2005
9 S L21

FILE 'REGISTRY' ENTERED AT 16:11:51 ON 25 FEB 2005

=> d 121 que stat
L1 STR



VAR G1=14/6

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L17 STR



VAR G1=14/6

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 3

CONNECT IS E2 RC AT 11

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L19 153 SEA FILE=REGISTRY SSS FUL L1

L21 12 SEA FILE=REGISTRY SUB=L19 SSS FUL L17

100.0% PROCESSED 153 ITERATIONS
SEARCH TIME: 00.00.01

12 ANSWERS

=> file zcaplus

FILE 'ZCAPLUS' ENTERED AT 16:12:08 ON 25 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 123 1-9 cbib abs hitstr hitrn

L23 ANSWER 1 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN

2002:356407 Document No. 137:278740 Aminolysis of cyclic
thioxocarbonate of (R,R)-di-tert-butyl tartrate: efficient access to
thio- and thiolcarbamates. Faissat, Ludovic; Chavis, Claude;
Montero, Jean-Louis; Lucas, Marc (ENSCM, Laboratoire de Chimie
Biomoléculaire, UMR 5032, Montpellier, 34296, Fr.). Journal of the
Chemical Society, Perkin Transactions 1 (10), 1253-1259 (English)
2002. CODEN: JCSPCE. ISSN: 1472-7781. OTHER SOURCES: CASREACT
137:278740. Publisher: Royal Society of Chemistry.

AB Aminolysis of cyclic thioxocarbonates derived from (R,R)-dialkyl
tartrates with secondary amines is described to afford efficiently
thio- and thiolcarbamates in a fast and high yielding reaction. For
example, diethylamine is reacted with (4R,5R)-2-thioxo-4,5-bis(tert-
butyloxycarbonyl)-1,3-dioxolane to give 95% (2R,3R)-di-tert-Bu
2-diethylthiocarbamoyloxy-3-hydroxysuccinate. Their stereochem. and
mechanism of formation are discussed.


IT 464188-92-9P

(prepn. of)

RN 464188-92-9 ZCAPLUS

CN Butanedioic acid, 2-[[bis(2-hydroxyethyl)amino]thioxomethoxy]-3-
hydroxy-, bis(1,1-dimethylethyl) ester, (2R,3R)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry. Rotation (-).



IT **464188-92-9P**
(prepn. of)

L23 ANSWER 2 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN
1998:1394 Document No. 128:72421 Texaphyrin-lipophilic
molecule-vesicle complexes, membrane incorporation of texaphyrins,
and use in diagnosis and therapy. Young, Stuart W.; Wright,
Meredith; Sessler, Jonathan L.; Mody, Tarak D.; Magda, Darren
(Pharmacyclics, Inc., USA; Board of Regents, University of Texas
System; Young, Stuart W.; Wright, Meredith; Sessler, Jonathan L.;
Mody, Tarak D.; Magda, Darren). PCT Int. Appl. WO 9746262 A2
19971211, 67 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR,
TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT,
BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE,
IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN:
PIXXD2. APPLICATION: WO 1997-US9501 19970604. PRIORITY: US
1996-657947 19960604.

AB Compns. are provided having a texaphyrin-lipophilic mol. conjugate
loaded into a biol. vesicle, as are methods for imaging, diagnosis
and treatment using the loaded vesicle are provided. For example,
liposomes or red blood cells loaded with a paramagnetic
texaphyrin-lipophilic mol. conjugate have utility as a blood pool
contrast agent, facilitating the enhancement of normal tissues,
magnetic resonance angiog., and marking areas of damaged endothelium
by their egress through fenestrations or damaged portions of the
blood vascular system. Liposomes or cells loaded with a
photosensitive texaphyrin-lipophilic mol. conjugate can be
photolyzed, allowing for a photodynamic therapy effect at the site
of lysis. Availability of red blood cells loaded with a
photosensitive texaphyrin-lipophilic mol. conjugate provides a
method for delivering a photodynamic therapeutic agent to a desired
site with a high concn. of oxygen. By presenting the agent in this

way, it is expected that a patient will experience less toxicity.


IT 197782-26-6D, metal complexes

(texaphyrin-lipophilic mol.-vesicle complexes, membrane incorporation of texaphyrins, and use in diagnosis and therapy)


RN 197782-26-6 ZCAPLUS

CN 8,11-Imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanamide, 20-[2-[(1-deoxyhexitol-1-yl)methylamino]-2-oxoethyl]-9,10-diethyl-N,N,N',N'-tetrakis(2-hydroxyethyl)-4,15-dimethyl- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 197782-26-6D, metal complexes

(texaphyrin-lipophilic mol.-vesicle complexes, membrane incorporation of texaphyrins, and use in diagnosis and therapy)


L23 ANSWER 3 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN

1997:650297 Document No. 127:316333 Use of a texaphyrin in photodynamic therapy of melanoma and other pigment-related lesions.


Woodburn, Kathryn W.; Quing, Fan; Young, Stuart W. (Pharmacyclics, Inc., USA; Woodburn, Kathryn W.; Quing, Fan; Young, Stuart W.). PCT Int. Appl. WO 9735617 A1 19971002, 56 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US5332 19970326. PRIORITY: US 1996-624311 19960326.

- AB The present invention involves the use of a photosensitive texaphyrin for the photodynamic treatment of a pigmented lesion, such as a melanodermic lesion, or of a lesion obscured by pigmented tissue, such as melaniferous tissue in a subject. In particular, the invention provides a treatment for the metastatic process of melanoma, and a method for inhibiting growth of established metastases of melanoma. The photosensitive texaphyrin may be a free-base texaphyrin or may be metalated with a diamagnetic metal. Preferably, the texaphyrin is metalated with lutetium. Heretofore, melanoma has been refractory to treatment with photodynamic therapy. The biodistribution in melanoma-bearing mice of a lutetium-texaphyrin complex, designated LuT2BET, was detd. Also described is the response to LuT2BET and photoirradn. in melanoma-bearing mice and in a patient with recurrent melanoma.
- IT **197782-26-6D**, metal complexes
(texaphyrins for photodynamic therapy of melanoma and other pigment-related lesions)
- RN **197782-26-6** ZCAPLUS
- CN **8,11-Imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanamide, 20-[2-[(1-deoxyhexitol-1-yl)methylamino]-2-oxoethyl]-9,10-diethyl-N,N,N',N'-tetrakis(2-hydroxyethyl)-4,15-dimethyl-** (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 197782-26-6D, metal complexes
(texaphyrins for photodynamic therapy of melanoma and other pigment-related lesions)

L23 ANSWER 4 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN
1997:105215 Document No. 126:113192 Cleavage of RNA using metal complexes. Magda, Darren; Sessler, Jonathan L. (Pharmacoclycs, Inc., USA; Board of Regents, the University of Texas System; Magda, Darren; Sessler, Jonathan, L.). PCT Int. Appl. WO 9638461 A1 19961205, 37 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1996-US8262 19960531. PRIORITY: US 1995-458347 19950602.

AB A particular class of metal complexes, specifically certain texaphyrin metal complexes, which both hydrolyze and photocleave RNA, and which also both hydrolyze RNA and photocleave DNA, is provided. The texaphyrin metal complex for each set of reactions has catalytic activity for phosphate ester hydrolysis and is photosensitive. A complex having the advantage of multiple activities can result in lower treatment dosages and lower treatment costs. The texaphyrin-oligonucleotide conjugates and present method of hydrolysis and photocleavage can be used for, e.g., antiviral and antibacterial therapy as well as cancer therapy (an oligonucleotide complementary to an oncogene, for example) and inflammatory responses that are caused by the overexpression of certain proteins.


IT 185827-27-4

(DNA and RNA photocleavage and RNA hydrolysis with texaphyrin metal complexes)


RN 185827-27-4 ZCAPLUS

CN Yttrium(2+), [1-[[[5,14-bis[3-[bis(2-hydroxyethyl)amino]-3-oxopropyl]-9,10-diethyl-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosin-20-yl-.kappa.N1,.kappa.N18,.kappa.N23,.kappa.N24,.kappa.N25]acetyl]methyamino]-1-deoxyhexitolato]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 2-A




IT 185827-27-4

(DNA and RNA photocleavage and RNA hydrolysis with texaphyrin metal complexes)

L23 ANSWER 5 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN
 1990:51739 Document No. 112:51739 Fluorescein derivatives as stable
 fluorescent labels for liposomes. Fiechtner, Michael D.; Bieniarz,
 Christopher; Shipchandler, Mohamed; Adamczyk, Maciej (Abbott
 Laboratories, USA). Eur. Pat. Appl. EP 297303 A2 19890104, 26 pp.
 DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL.
 (English). CODEN: EPXXDW. APPLICATION: EP 1988-108778 19880601.
 PRIORITY: US 1987-67833 19870629.

GI



I

AB Fluorescein derivs. I [R1 = pyridoxamide, COOH, XN(Y)(Z); R2, R3 = H, XN(Y)(Z); X = C:O, aminothiocarbonyl, methylene; Y = H, lower alkyl, carboxy alkyl, lower alkylol; Z = carboxy alkyl; lower alkylol, mono- or disaccharide, pyridoxyl] have a fluorescence spectrum and quantum yield characteristics similar to those of fluorescein. The compds. are readily synthesized and purified and are readily sol. in water at self-quenching concns. Due to the presence of polar polyhydroxy group substituents and the absence of metal-chelating groups, these fluorescein derivs. are susceptible to minimal leakage across liposome membranes and have fluorescence characteristics minimally sensitive to the presence of metal ions. Compds. of the invention are thus exceptionally suitable for use in the development of highly storage stable liposome preps. to be employed in immunolytic assays involving human body fluid samples. I (R1 = CON(CH3)CH2(CHOH)4CH2OH; R2 = R3 = H) (II; 5(6)-carboxyfluorescein-N-methylglucamide) was prepd. by reacting 5(6)-carboxyfluorescein-N-hydroxysuccinimide ester (prepd. from 5(6)carboxyfluorescein and N-hydroxysuccinimide) 95 with N-methyl-D-glucamine 39 and triethylamine 24 g in anhyd. HCON(CH3)2 for 12 h at room temp., followed by HPLC on silica gel using Me2CO:AcOH (50:1) with a 2-10% MeOH gradient. II in H2O (pH 7.2 with 6 N NaOH) and HEPES was added to a thin film of a mixt. of sphingomyelin:cholesterol:stearic acid (45:50:5) at 37.degree. for 15 min, vortexed, heated to 50.degree. and then slowly cooled to (2.degree./h) to 4.degree.. The liposomes were then washed and stored in isotonic buffer. Encapsulation of II after 121 days was 97.7%, compared to 95.9 and 41.2%, resp., for 5(6)-carboxyfluorescein and fluorescein.



IT 124452-58-0P

(prepn. of, as fluorescent labels for liposomes for immunoassays)

RN 124452-58-0 ZCAPLUS

CN D-Glucitol, 1-[[[4',5'-bis[[bis(2-hydroxyethyl)amino]methyl]-3',6'-

dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-6(or 7)-yl]carbonyl]methylamino]-1-deoxy- (9CI) (CA INDEX NAME)



IT 124452-58-0P

(prepn. of, as fluorescent labels for liposomes for immunoassays)

L23 ANSWER 6 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN

1989:231103 Document No. 110:231103 Preparation of 3-(N,N-polyoxyethylene-N-alkylammonio)-2-hydroxypropyl-1-tartrate. Kłopotek, Alojzy; Iwanczuk, Edward (Instytut Chemii Przemysłowej, Pol.). Pol. PL 136721 B1 19870530, 6 pp. (Polish). CODEN: POXXA7. APPLICATION: PL 1981-231990 19810702.

AB Title compds. $RN^+[H(OCH_2CH_2)_x][(CH_2CH_2O)_yH]CH_2CH(OH)CH_2O_2CCH(OH)CH(OH)CO_2^-$ (I; R = C4-36 hydrocarbyl: x, y = 1-15) useful as antibacterials, surfactants and antistatics, are prepd. 1-Chloro-2,3-epoxypropane was added dropwise to Na H tartrate to give $ClCH_2CH(OH)CH_2O_2CCH(OH)CH(OH)CO_2Na$ which was treated with $Me(CH_2)_{16}CH_2N(CH_2CH_2OH)_2$ to give I (R = C18H38; x, y = 1) (II) in 98% yield. The min. inhibitory concn. of II was lower at pH 3.6 than at pH 10 against e.g., *Escherichia coli*.

IT 120762-87-0P

(prepn. of, as antibacterial and surfactant)


RN 120762-87-0 ZCAPLUS

CN Octadecen-1-aminium, N-[3-(3-carboxy-2,3-dihydroxy-1-oxopropoxy)-2-hydroxypropyl]-N,N-bis(2-hydroxyethyl)-, inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 120762-86-9

CMF C29 H57 N 09



IT 120762-87-0P

(prepn. of, as antibacterial and surfactant)

L23 ANSWER 7 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN

1976:45895 Document No. 84:45895 Antistatic polyamide composition. Kuenzel, Hans E.; Wolf, Gerhard Dieter; Brokmeier, Dieter; Bentz, Francis (Bayer A.-G., Fed. Rep. Ger.). Ger. Offen. DE 2416206 19751016, 24 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1974-2416206 19740403.

AB Antistatic polyamide fibers are produced from polyamide melts contg., as antistatic agent, 1.5-15% of a polyalkylene glycol ether with certain urethane end groups. Thus, .epsilon.-caprolactam 130, .epsilon.-aminocaproic acid 15 and H37C18(OCH2CH2)20O2CN(CH2CH2OH)2 [57829-59-1] 2 g were heated 3 hr at 270.degree. in N. The fiber spun from this melt had surface resistance (DIN 54345) as prepd. 4.times.10⁹ .OMEGA.cm² and 2.times.10¹¹ .OMEGA.cm² after 1.5, and 10 washings, in contrast with 5.times.10¹² .OMEGA.cm² after the 1st wash for fibers with no antistatic agent added.


IT 57829-57-9

(antistatic agents, for polyamide fibers, prepn. of)


RN 57829-57-9 ZCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-[[[bis(2-hydroxyethyl)amino]carbonyl]oxy]-, ether with D-mannitol (6:1) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 57829-57-9

(antistatic agents, for polyamide fibers, prepn. of)

L23 ANSWER 8 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN

1976:8854 Document No. 84:8854 Skin-treating and skin-protective composition. Moeller, Hinrich; Osberghaus, Rainer; Gloxhuber, Christian; Braig, Siegfried (Henkel und Cie. G.m.b.H., Fed. Rep. Ger.). Ger. Offen. DE 2404070 19750814, 25 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1974-2404070 19740129.

AB Incorporation of N-(polyhydroxyalkyl)amines, prepd. by catalytic


reductive amination of monosaccharides or uronic acids, into skin care preps. promoted water retention by the skin, thus maintaining its softness and elasticity. For example, N-(2,3-dihydroxypropyl)glucamine [57273-24-2] was prepd. by catalytic hydrogenation of the reaction product of 19.6 g D-glucose [50-99-7] and 18.2 g 2,3-dihydroxypropylamine [616-30-8] in H₂O-MeOH at 50-70.degree. and 180 atm with Raney Ni. A baby cream was prepd. from e.g. N-(.beta.-piperazinoethyl)glucamine lactate [57288-68-3] 5.0, Dehymuls E 7.0, decyl oleate 10.0, vaseline 10.0, wool fat 5.0, boric acid 0.2, talcum 12.0, ZnO 8.0, Nipagin M 0.2, and water 42.6 parts by wt.

IT 57273-26-4P

(prepn. and skin-moisturizing activity of)

RN 57273-26-4 ZCAPLUS

CN D-Glucitol, 1-[[3-[bis(2-hydroxyethyl)amino]propyl]amino]-1-deoxy- (9CI) (CA INDEX NAME)



IT 57273-26-4P

(prepn. and skin-moisturizing activity of)

L23 ANSWER 9 OF 9 ZCAPLUS COPYRIGHT 2005 ACS on STN

1975:497843 Document No. 83:97843 N-Alkyl-N'-polyhydroxyalkyl-N'-aminoalkyl ureas and their use in washing compositions. Eckert, Hans W. (Henkel und Cie. G.m.b.H., Fed. Rep. Ger.). Ger. Offen. DE 2349278 19750410, 18 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1973-2349278 19731001.

AB Glucose reacted with RRN(CH₂)₃NH₂ (R = Me, Et, CH₂CH₂OH) and EtOH contg. Raney Ni in an autoclave followed by treatment with R₁NCO [R₁ = Me(CH₂)_n, n = 11, 13, 15, 17] to give R₁NHCON[CH₂[CH(OH)]₄CH₂OH](CH₂)₃NRR, which showed a fluorescent whitening activity on wool, polypropylene, polyester, and polyurethane textiles.


IT 56653-22-6P 56653-23-7P 56653-24-8P

56653-25-9P

(prepn. and fluorescent brightening activity of)


RN 56653-22-6 ZCAPLUS

CN D-Glucitol, 1-[[3-[bis(2-hydroxyethyl)amino]propyl][(dodecylamino)carbonyl]amino]-1-deoxy- (9CI) (CA INDEX NAME)




RN 56653-23-7 ZCAPLUS

CN D-Glucitol, 1-[[3-[bis(2-hydroxyethyl)amino]propyl]][(tetradecylamino)carbonyl]amino]-1-deoxy- (9CI) (CA INDEX NAME)




RN 56653-24-8 ZCAPLUS

CN D-Glucitol, 1-[[3-[bis(2-hydroxyethyl)amino]propyl]][(hexadecylamino)carbonyl]amino]-1-deoxy- (9CI) (CA INDEX NAME)



RN 56653-25-9 ZCAPLUS

CN D-Glucitol, 1-[[3-[bis(2-hydroxyethyl)amino]propyl]][(octadecylamino)carbonyl]amino]-1-deoxy- (9CI) (CA INDEX NAME)



IT 56653-22-6P 56653-23-7P 56653-24-8P
 56653-25-9P
 (prepn. and fluorescent brightening activity of)